Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
07 Oct 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216297
05 Jul 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211943
18 Mar 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217183
08 Feb 2022
// BUSINESSWIRE
16 Nov 2021
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212533
Details:
Likmez(metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Likmez
Study Phase: ApprovedProduct Type: Small molecule
Recipient: Appili Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Appili Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspens...
Details : Likmez(metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organi...
Brand Name : Likmez
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 25, 2023
Details:
Under the terms of the amended agreement, Saptalis will assume responsibility for development and commercialization of ATI-1501 in Europe and Latin America (collectively, the “Expanded Territories”).
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: ATI-1501
Study Phase: Phase IProduct Type: Small molecule
Recipient: Appili Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 08, 2022
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
Details : Under the terms of the amended agreement, Saptalis will assume responsibility for development and commercialization of ATI-1501 in Europe and Latin America (collectively, the “Expanded Territories”).
Brand Name : ATI-1501
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 08, 2022
RLD : Yes
TE Code : AT
ACETIC ACID, GLACIAL; HYDROCORTISONE
Dosage Form : SOLUTION/DROPS; OTIC
Proprietary Name : VOSOL HC
Dosage Strength : 2%;1%
Approval Date : 1982-01-01
Application Number : 12770
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AT
RLD : No
TE Code : AT
Dosage Form : SOLUTION; TOPICAL
Proprietary Name : CLOBETASOL PROPIONATE
Dosage Strength : 0.05%
Approval Date : 2019-10-02
Application Number : 211494
RX/OTC/DISCN : RX
RLD : No
TE Code : AT
RLD : No
TE Code : AB
Dosage Form : EMULSION; OPHTHALMIC
Proprietary Name : CYCLOSPORINE
Dosage Strength : 0.05%
Approval Date : 2024-07-05
Application Number : 211943
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AA
Dosage Form : SOLUTION; ORAL
Proprietary Name : GLYCOPYRROLATE
Dosage Strength : 1MG/5ML
Approval Date : 2024-10-07
Application Number : 216297
RX/OTC/DISCN : RX
RLD : No
TE Code : AA
RLD : No
TE Code : AB
Dosage Form : SOLUTION; ORAL
Proprietary Name : METFORMIN HYDROCHLORIDE
Dosage Strength : 500MG/5ML
Approval Date : 2020-03-03
Application Number : 211309
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code :
Dosage Form : SUSPENSION; ORAL
Proprietary Name : LIKMEZ
Dosage Strength : 500MG/5ML
Approval Date : 2023-09-22
Application Number : 216755
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?